xuzhou, ChinaAnd the November 25, 2022 /PRNewswire/ — inQB8 Medical Technologies, LLC (inQB8), in partnership with Peijia Medical Limited (Peijia, (9996.HK)), today announced that it has successfully implanted a MonarQ Transcatheter Tricuspid Valve in a 75-year-old female with triple regurgitation The balconies are severe. Trans-Jugular TTVR procedure was performed on November 21, 2022For Humanitarian Heart Center, Rigshospit University Hospital, Copenhagen, Denmarkby interventional cardiologists Prof. Lars Sondergaard, MD, Prof. M. Ole De Becker MD. and cardiothoracic surgeon Morten Smirop, MD, Jacob Mueller MD. (echocardiologist), Hass Müller Sorensen. MD (Anesthesiologist), along with inQB8 Co-Founder, CEO, CMO, Cardiac Surgeon, Arshad QadriMD
“We are grateful for the opportunity to work with Dr. Quadri again, along with the team from inQB8, to provide an exciting new treatment option for this patient for whom no other alternatives were available,” said Dr. Lars Sondergaard. “Due to multiple risk factors and anatomical limitations, neither conventional tricuspid valve surgery nor transcatheter edge-to-edge tricuspid repair were options for this patient. Through careful review and consideration within our team, we determined that TTVR with the MonarQ System could offer the potential to relieve symptoms And improving the quality of life for this patient. The valve was successfully implanted with excellent function.”Read:Simple computer program may help personalize cancer treatment
“I am delighted to be working with Dr. Lars Sondergaard and his expert team at Rigshospitalet on this next chapter in transcatheter valve development. The MonarQ Transcatheter Tricuspid Valve (TTV) has a unique BioDynamic Tethering System that utilizes and maintains the natural motion of the heart securing the implant to the original leaflets, distributing the loads systolic, and reduce paravalvular leaks over a wide range of original annulus sizes,” he said Arshad Qadri, MD, Cardiac Surgeon and Co-Founder, CEO and Chief Marketing Officer of inQB8. “By addressing not only the anatomical requirements but also the physiological needs of the tricuspid valve, Dr. Quadri and I believe the MonarQ TTVR System will turn the page on the treatment of tricuspid valve regurgitation; an extremely insidious and disabling disease of this forgotten disease,” said Mr. Brent RatzCo-founder and CEO of inQB8.
“In the past few years, the need for a transcatheter tricuspid valve replacement solution has become increasingly evident. As Peijia looks to expand its presence globally and build its structural heart portfolio, our joint investment in inQB8 and MonarQ TTVR technology was a natural choice,” said Dr. Michael Chang, Chairman and CEO of Peijia Medical. “MonarQ’s first successful implantation in humans marks an exciting first step in bringing this life-saving and life-enhancing technology to more and more patients around the world,” said Dr. Jianfong Tan, Chief Technology Officer of Peijia Medical.Read:Symptoms of Covid affecting the fully vaccinated
About Peijia Medical Limited
Peijia Medical (09996.HK) was established in 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional procedural medical device market in China, and aims to become the world-renowned medical device platform providing comprehensive treatment solutions for cardiovascular and skeletal diseases.
About inQB8 Medical Technologies, LLC
inQB8 Medical Technologies, LLC is a privately owned and based medical device incubator Massachusetts With additional offices in Irvine, California. This is the second collaboration between Dr. Arshad Qadri, MD And the Brent Ratz, MBA, whose partnership began 16 years ago with the co-foundation of CardiAQ Valve Technologies, the world’s first transseptal mitral valve replacement (TMVR) system. inQB8 focuses on developing novel international solutions for major cardiovascular diseases including structural heart problems, aortic disease and heart failure and accelerates projects through prototyping and preclinical testing until they are ready to be acquired or developed as a separate cardiovascular start-up. -UBS. in June 2021Peijia Medical announced a strategic partnership with inQB8 and agreed to acquire MonarQ TTVR technology, which it continues to develop in QB8 on its behalf.Read:How to Help Kids With Anxiety: 8 Tips for Parents
Any forward-looking statements are subject to risks and uncertainties such as those described in Peijia Medical’s periodic reports on file with HKEx. Actual results may differ materially from expected results.
Warning: The MonarQ transcatheter tricuspid valve replacement system is still in the early stages of development. It will not be available for clinical trials until further notice and is not available for sale.
Logo – https://mma.prnewswire.com/media/1954815/Peijia_Logo.jpg
Logo – https://mma.prnewswire.com/media/1954814/inQB8_Logo.jpg
SOURCE Peijia Medical Limited